BRKR Stock Recent News

Under a strategic partnership with Alamar Biosciences, Biognosys is a provider of choice of NULISA multiplex assay services for biopharma research The NULISAseq™ CNS Disease and Inflammation panels are now available for customers as a contract research service from Biognosys' high-end proteomics facility in Europe By offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomics ZURICH and NEWTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in next-generation proteomics solutions for drug discovery and development, announced today the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: 2024 Wells Fargo Healthcare Conference in Boston, MA Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time Morgan Stanley 22nd Annual Global Healthcare Conference in New York City Friday, September 6, 2024, at 10:00 a.m. Eastern Time Live audiovisual webcasts of the presentation.

Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.

Evaluate Bruker's (BRKR) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Bruker Corporation (NASDAQ:BRKR ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Joe Kostka - Associate Director, Investor Relations Frank Laukien - President and CEO Gerald Herman - Executive Vice President and CFO Conference Call Participants Puneet Souda - Leerink Partners Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Josh Waldman - Cleveland Research Operator Good day. And welcome to the Bruker Corporation Second Quarter 2024 Earnings Call.

Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.

Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.

The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.

Bruker (BRKR) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.50 per share a year ago.